.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,700,795

« Back to Dashboard

Details for Patent: 5,700,795

Title: Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of type II diabetes
Abstract:Disclosed are methods for improving various aberrant metabolic indices in mammals including humans by administration of muscarinic (particularly M1) receptor antagonists alone or in combination with prolactin inhibiting compounds. Preferably the administration takes place at a predetermined time (or, if a combination of muscarinic receptor antagonist and prolactin inhibitor is used, at different predetermined times) during a 24-hour period when the administration is effective (or its effect more pronounced). The invention has application in the treatment of lipid and glucose metabolism disorders.
Inventor(s): Cincotta; Anthony H. (Andover, MA), Meier; Albert H. (Baton Rouge, LA), Wilson; John M. (Charlestown, MA)
Assignee: The General Hospital Corporation (Boston, MA) The Board of Supervisors of Louisiana State University and Agricultural (Baton Rouge, LA)
Filing Date:Jun 01, 1995
Application Number:08/458,085
Claims:1. A method of treating Type II diabetes in a mammalian subject in need of such treatment comprising administering to said subject an amount of a muscarinic receptor antagonist selective for the M1 receptor at a predetermined time during a 24-hour period, said amount and said time being effective to accomplish at least one of: decreasing hyperinsulinemia, decreasing hyperglycemia, and decreasing insulin resistance in said subject.

2. The method of claim 1 wherein said subject is human.

3. The method of claim 1 wherein said antagonist is selected from the group consisting of:

methantheline, ipratropium, propantheline, dicyclomine, scopolamine, methylscopolamine, telenzepine, benztropine, QNX-hemioxalate, hexahydro-sila-difenidol hydrochloride and pirenzepine.

4. The method of claim 3 wherein said antagonist is selected from the group consisting of pirenzepine and methyl scopolamine.

5. The method of claim 2 wherein said antagonist is selected from the group consisting of:

methantheline, ipratropium, propantheline, dicyclomine, scopolamine, methylscopolamine, telenzepine, benztropine, QNX-hemioxalate, hexahydro-sila-difenidol hydrochloride and pirenzepine.

6. The method of any one of claims 1-4 and 5, said administration of said antagonist taking place at a predetermined time within a 24-hour period at which the glucose or lipid metabolism of said mammal is responsive to said antagonist.

7. The method of claim 1 wherein said M1 muscarinic antagonist is administered at a single predetermined time.

8. The method of claim 1 wherein said administration is continued for a period of at least 10 days up to about 180 days.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc